Anti-IL-6R/CD126 antibody

Anti-IL-6R/CD126 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Mouse monoclonal to IL-6R/CD126

B/N

Human IL-6R / CD126
No cross-reactivity with rat IL6R (501482), mouse IL6R (500652) and canine IL6R (502343) in ELISA assay

CD126 antibody; IL6R antibody; IL-6R antibody; IL-6R-1 antibody; IL6RA antibody; IL-6R-alpha antibody; MGC104991 antibody

Mouse IgG1

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IL-6R / CD126 (rh IL-6R / CD126; NP_000556.1; Met1-Pro365). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

Monoclonal

0.2 μm filtered solution in PBS (pH7.4) + 5% Trehalose Dihydrate

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Block - This IL6R Neutralizing Antibody can not block the binding of recombinant IL6 to its recombinant receptor IL6 Rα.
Neutralization - The neutralization activity of IL6R Neutralizing Antibody is measured by its ability to neutralize IL6 Rα-mediated inhibition of proliferation in the M1 mouse myeloid leukemia cell line. The Neutralization Titer (IC50) is typically 0.15-0.6 µg/mL in the presence of 50 ng/mL Recombinant Human IL6 Rα and 100 ng/mL Recombinant Human IL6.

Interleukin 6 receptor (IL-6R) also known as CD126 (Cluster of Differentiation 126) is a type I cytokine receptor. The low concentration of a soluble form of IL-6 receptor (sIL-6R) acts as an agonist of IL-6 activity. In the IL-6R/CD126/IL6R system, both a membrane-bound IL-6R and a sIL-6R protein are able to mediate IL-6 signals into the cells through the interaction of gp130. The resulting IL-6/sIL-6R protein complex is also capable of binding to gp130 and inducing intracellular signalling. Through this so-called 'trans-signalling' mechanism, IL-6 is able to stimulate cells that lack an endogenous mIL-6R. High levels of IL-6 and sIL-6R have been reported in several chronic inflammatory and autoimmune diseases as well as in cancer.

• Barill S, et al. (2000) The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 11(4): 546-51.
• Kang KW, et al. (2007) Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells. Free Radic Biol Med. 42(2): 215-27.